Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Zeftera, Mabelio
Ceftobiprole is a fifth-generation cephalosporin antibiotic with a broad spectrum of activity against Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. It is used to treat complicated skin and skin structure infections (cSSSIs) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). Ceftobiprole works by inhibiting bacterial cell wall synthesis, leading to bacterial cell death.
For the treatment of complicated skin and skin structure infections (cSSSIs) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP).
Outcome:
Increased ceftobiprole levels
Mechanism:
Reduced renal excretion
Outcome:
Disulfiram-like reaction (rare)
Mechanism:
Inhibition of aldehyde dehydrogenase
Outcome:
May increase absorption of ceftobiprole
Mechanism:
Enhanced solubility/absorption
Most likely new formulation: Liposomal ceftobiprole for improved tissue penetration (Year: 2026, 60% confidence)
Based on current usage trends and resistance patterns, there is a 70% likelihood of ceftobiprole maintaining its efficacy against MRSA over the next 5 years.
Antibiotic, Cephalosporin (Fifth-Generation)
Cephalosporin